🔗 Share this article

As the US proceeds with unprecedented changes to its immunization recommendations, one figure appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by casting doubt on COVID-19 shots during the global health crisis and has zeroed in on possible deaths following COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Program

Public health authorities planned to reveal sweeping changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of step with much of the global community with no evidence for benefit. This reveal has been delayed until the new year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to present at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to lead the office this year.

A Shift at the Agency

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the agency – and it signals a renewed priority upon dismantling already-approved immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific childhood shot schedules in the US to become more similar to Denmark, a nation with universal health coverage and a population approximately the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on vaccination policy – usually the purview of Dr. Prasad, chief of the FDA’s CBER – rather than drug regulation.

Questions Over Qualifications

Dr. Høeg has no apparent experience in pharmaceutical research, approval processes or leadership, which has been standard for former directors of the biologics center. She has served at the FDA as a top consultant to the FDA chief and CBER since March.

“It seems she lacks to have the necessary background” for leading the CDER, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in managing a large organization. She has no expertise in industry regulation.”

Former directors of the center would “understand legal statutes and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Clearly, she lacks the kind of background that previous people who ran the center have had.”

The drug center has an vast workload at the agency, the former commissioner stated.

“Many people just focuses on the new drug program, but the generic program approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and so forth, and each of these have to be supervised,” Dr. Woodcock noted. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a major management aspect to the role, which oversees in excess of 5,000 personnel. “It is a massive administrative position, if you do it right,” she said.

Response and Controversial Initiatives

When asked about inquiries about Høeg’s fitness for the role and whether this assignment represents greater collaboration among FDA leaders on immunizations, a press secretary said that the “inquiries rely on inaccurate premises”.

“This background is consistent with the responsibilities of her job,” the spokesperson stated, citing the time Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's new priority voucher program, a disputed one-day therapy clearance system that apparently worried her former heads. “By what process are these therapies being selected for this fast-track system? Who makes the calls?” Howard asked. “There is a lot of confidentiality going on at the FDA right now.”

Overall, he said, “the agency appears to be shifting towards more relaxed oversight of most medications, aside from vaccines.”

Public History on Immunizations

With immunizations, Dr. Høeg has a more established, if troubling, history, critics said. She released a analysis using non-validated volunteer-provided data to estimate the frequency of heart inflammation following Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Part of her “wish list” for the incoming administration included revising guidelines for recently developed shots and ending “non-essential” vaccines, she stated post-election on a online show. At the FDA, Høeg has allegedly floated the idea of barring teenage boys from getting COVID-19 vaccinations.

“She is an all-around true believer who commences with her conclusions and works backwards to accommodate the science in a very disingenuous, fraudulent manner,” Howard said.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|